The UK soul screaming superstar had whose hit record ’21’ was multi Grammy Award winning machine last year. Adele, 24 wrote on her weblog that she is expecting with her guy, Simon Konecki.

Although ’21’ was a blockbuster selling more than 9 million copies, she has made it clear in the past that she is not in a hurry to make another album. Having children is clearly a priority for the star whose album, for 70 strait weeks, has been in the top 10. This week it is still sitting in no 7 and had been in the coveted first spot for 24 out of those 70 weeks.

This news should come as no suprise to hard core Adele fans as she has told magazinze that she really wants to be a “mum”. She has also stated that she wants to have 3 sons by the time she hits 30. Sounds like she will be pretty busy for the next 6 years.

Adele’s guy Simon runs a charity called Drop4Drop. The charity aims to get developing countries the clean water they so desperately need. They have been an item for almost a year.

Here is her note posted on her website:

“I’m delighted to announce that Simon and I are expecting our first child together, I wanted you to hear the news direct from me, obviously we’re over the moon and very excited but please respect our privacy at this precious time.”

Lets hope that her next album is filled with happy songs, although she has not given date for any projects forthcoming.

On Tuesday, the Medicines Patent Pool and the United States pharmaceutical company Gilead Sciences announced a deal to boost HIV drug access in developing countries by introducing generic manufacturing.

Under the new licensing agreement for HIV drugs, tenofovir, emtricitabine, cobicistat, and elvitegravir will be allowed to have low-cost copycats. Also included in their licensing deal is the creation of a new combination drug called the Quad.

Executive director of the Medicines Patent Pool, Ellen ‘t Hoen, said that this license deal marks a milestone in the treatment of HIV. Because of this, HIV medicines will become more accessible and cheap. People in developing countries have to wait for years before they can get their hand on recent health technologies. Because of the new agreement with Gilead Sciences, people from poorer countries can now get these HIV medicines without delay.

All thanks to generic drugs, the cost of HIV treatment has dropped from $10,000 in 2000 to $86 per patient per year. There is still, however, a need for more expensive drugs to give doctors options because some patients do not respond well to generic medicine. Also, HIV mutates which puts patients at risk for long-term drug resistance problem.

This is the first of its kind; the first agreement between a pharmaceutical company and Medicine Patents Pool. This is a good step towards overcoming our problems with the increasing HIV rate.

For the first time in a very long time- or at least since the recession started- credit card executives are seeing bright sunny days and are looking far beyond the losses brought by the financial crisis. This is a really good thing considering the fact that the government is planning to tighten their grip on credit card companies.

Over the past few months, credit card company losses are falling. The overwhelming consumer acceptance of the smartphone payment systems and all other technologies has given credit card companies the opportunity to garner long-term revenue growth.

Now, executives strongly believe that they can easily do something to work around the effects of the recent regulatory changes of the card industry.

Credit card executive Stephen Eulie said that he is still very optimistic. There are no negative effects of our current economy that they cannot do something about, he said. Eulie spoke to Reuters in the credit card industry conference conducted every year.

In the recent years, most of the topics discussed in the conference are about the new regulations in place. Talks about the credit card law passed in 2009 and its lingering effects dominated the previous conferences. The Dodd-Frank financial reform law was also constantly a hot topic in the previous years.

However, banks are more positive and credit card companies are tapping new technologies this year to invest in developing countries wherein people use credit card as a luxury and not a necessity.

One of the conference attendee said that that the credit card industry has stopped finding ways to cease the regulations, and started looking for ways on how to get around it.